Craft

Mustang Bio

Stock Price

$0.3

2024-10-29

Market Capitalization

$11.2 M

2024-10-29

Mustang Bio Summary

Company Summary

Overview
Mustang Bio is a clinical-stage biopharmaceutical company that specializes in the development of cell and gene therapies. It focuses on three areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders.
Type
Public
Status
Active
Founded
2015
HQ
Worcester, MA, US | view all locations
Website
https://www.mustangbio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Manuel Litchman

    Manuel Litchman, President, Chief Executive Officer, Director

  • Greg Furrow

    Greg Furrow, Chief Quality Officer

  • Kerry Biron, VP & Head, Clinical Operations

    • Matthew Wein

      Matthew Wein, VP & General Counsel

    Operating MetricsView all

    Facility Space Leased, sq. ft.

    53.5K
    98.0%

    FY, 2022

    LocationsView all

    1 location detected

    • Worcester, MA HQ

      United States

      377 Plantation Street

    Mustang Bio Financials

    Summary Financials

    Net income (Q1, 2026)
    ($955.0K)
    Cash (Q1, 2026)
    $16.3M
    EBIT (Q1, 2026)
    ($1.1M)

    Footer menu